Numis Securities Ltd Boosts Vectura Group PLC (VEC) Price Target to GBX 252
Vectura Group PLC (LON:VEC) had its price objective raised by Numis Securities Ltd from GBX 246 ($3.21) to GBX 252 ($3.29) in a research report sent to investors on Monday. They currently have a buy rating on the stock.
A number of other brokerages have also weighed in on VEC. Citigroup Inc. restated a buy rating and issued a GBX 215 ($2.81) target price on shares of Vectura Group PLC in a research note on Thursday, July 28th. Stifel Nicolaus restated a buy rating and issued a GBX 242 ($3.16) target price on shares of Vectura Group PLC in a research note on Tuesday, August 30th. Peel Hunt restated a buy rating and issued a GBX 200 ($2.61) target price on shares of Vectura Group PLC in a research note on Tuesday, July 19th. JPMorgan Chase & Co. restated an overweight rating and issued a GBX 230 ($3.00) target price on shares of Vectura Group PLC in a research note on Wednesday, July 6th. Finally, FinnCap reiterated a buy rating and issued a GBX 225 ($2.94) price objective on shares of Vectura Group PLC in a report on Tuesday, August 30th. Eight equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of Buy and an average price target of GBX 222.25 ($2.90).
Shares of Vectura Group PLC (LON:VEC) opened at 141.10 on Monday. The firm has a 50-day moving average price of GBX 140.10 and a 200-day moving average price of GBX 156.17. Vectura Group PLC has a one year low of GBX 122.90 and a one year high of GBX 200.10. The company’s market capitalization is GBX 579.38 million.
In other news, insider Derodra,Andrew sold 263,364 shares of the stock in a transaction that occurred on Thursday, July 7th. The stock was sold at an average price of GBX 152 ($1.98), for a total value of £400,313.28 ($522,533.98).
About Vectura Group PLC
Vectura Group plc is a product development company. The Company focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to pharmaceutical companies.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.